Figure 2, COMPASS Design Schematic - Clinical Review Report: Rivaroxaban ( Xarelto) - NCBI Bookshelf
Rivaroxaban con o sin Aspirina en enfermedad cardiovascular estable – Estudio COMPASS
The COMPASS Trial | Circulation
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin - ScienceDirect
COMPASS Trial Shows Rivaroxaban and Aspirin Lowers Major Adverse Limb Events in Peripheral Artery Disease | DAIC
Épisode 10 : Étude COMPASS - BaladoCritique : Club de lecture médical - Université de Sherbrooke
Studio COMPASS: efficacia dell'associazione rivaroxaban ed aspirina nei pazienti con vasculopatia aterosclerotica stabile - ATBV
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial - The Lancet
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial | Journal of the American College of Cardiology
COMPASS: Clinical Trial - Post Revascularization & Chronic PAD | XARELTO® ( rivaroxaban) HCP
COMPASS | Xarelto Global
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial - ScienceDirect
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease | DAIC
COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease | tctmd.com
COMPASS-CABG
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial | Journal of the American College of Cardiology
عبدالله خربوش on X: "COMPASS trial: Rivaroxaban with or without aspirin in stable CVD. The NEJM. 2017. epub 2017-08-27:1-12. Further evidence of increased major bleeding with this approach will necessitate careful consideration
COMPASS study of Janssen's rivaroxaban to end early for efficacy - 526 Fulham Rd, Fulham, London SW6, UK
Rivaroxaban Shows Superiority Over Aspirin in Patients With Coronary and Peripheral Artery Disease | DAIC
COMPASS study of rivaroxaban to end early for efficacy - Cardiovascular News
C. Michael Gibson MD on X: "Here is the design of the COMPASS trial of > 27,000 patients that was shut down due to overwhelming superiority of rivaroxaban https://t.co/abziReBQNk" / X
